Literature DB >> 6538436

Defect in glycosylation of erythrocyte membrane proteins in congenital dyserythropoietic anaemia type II (HEMPAS).

M N Fukuda, T Papayannopoulou, E C Gordon-Smith, H Rochant, U Testa.   

Abstract

Congenital dyserythropoietic anaemia type II (HEMPAS) is a hereditary disease believed to be caused by a membrane abnormality of erythroid cells. Since the molecular basis of this membrane abnormality has not yet been defined, membrane glycoproteins of HEMPAS erythrocytes were analysed by cell surface labelling and endo-beta-galactosidase digestion in this study. HEMPAS erythrocytes showed an abnormal glycoprotein profile when cells were labelled by the galactose oxidase/NaB[3H]4 method; Band 3 and Band 4.5 glycoproteins in HEMPAS are labelled but with less intensity although normally these proteins are the major components revealed by the same method. Instead, in HEMPAS, labelled lactosaminoglycans were found as a lower molecular weight glycoconjugate (HEMPAS glycan). HEMPAS glycan was characterized by micelle formation, a monomer molecular weight of 4000, susceptibility to endo-beta-galactosidase and resistance to protease. These characteristics suggest that HEMPAS glycan has the nature of macroglycolipid. Proteins of Band 3 and the glucose transport protein (a component of Band 4.5), which were detected by antibodies showed a slightly decreased molecular weight in HEMPAS erythrocytes compared to those from normal erythrocytes, which was consistent with the decreased glycosylation of these proteins. The results indicate that anomalies in glycosylation occurred specifically in lactosaminoglycan glycoproteins of HEMPAS erythrocytes.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538436     DOI: 10.1111/j.1365-2141.1984.tb01271.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  7 in total

1.  Incomplete synthesis of N-glycans in congenital dyserythropoietic anemia type II caused by a defect in the gene encoding alpha-mannosidase II.

Authors:  M N Fukuda; K A Masri; A Dell; L Luzzatto; K W Moremen
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  Characterization of the N-glycosylation phenotype of erythrocyte membrane proteins in congenital dyserythropoietic anemia type II (CDA II/HEMPAS).

Authors:  Jonas Denecke; Christian Kranz; Manfred Nimtz; Harald S Conradt; Thomas Brune; Hermann Heimpel; Thorsten Marquardt
Journal:  Glycoconj J       Date:  2007-12-29       Impact factor: 2.916

3.  The Drosophila neurally altered carbohydrate mutant has a defective Golgi GDP-fucose transporter.

Authors:  Christoph Geisler; Varshika Kotu; Mary Sharrow; Dubravko Rendić; Gerald Pöltl; Michael Tiemeyer; Iain B H Wilson; Donald L Jarvis
Journal:  J Biol Chem       Date:  2012-06-28       Impact factor: 5.157

4.  Congenital dyserythropoietic anemia type II: morphological characterization of the erythroid colonies (BFU-E) from the bone marrow and peripheral blood of two patients.

Authors:  L Florensa; S Woessner; C Besses; F Solé; J Sans-Sabrafen
Journal:  Ann Hematol       Date:  1994-08       Impact factor: 3.673

Review 5.  Congenital disorders of glycosylation: review of their molecular bases, clinical presentations and specific therapies.

Authors:  T Marquardt; J Denecke
Journal:  Eur J Pediatr       Date:  2003-03-15       Impact factor: 3.183

Review 6.  The COPII pathway and hematologic disease.

Authors:  Rami Khoriaty; Matthew P Vasievich; David Ginsburg
Journal:  Blood       Date:  2012-05-14       Impact factor: 22.113

7.  Expression of alpha-GalNAc glycoproteins by breast cancers.

Authors:  S A Brooks; A J Leathem
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.